Details for Patent: 12,128,059

Which drugs does patent 12,128,059 protect, and when does it expire?

Patent 12,128,059 protects CABTREO and is included in one NDA.

This patent has twelve patent family members in ten countries.

Summary for Patent: 12,128,059

Title:	Topical compositions
Abstract:	The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.
Inventor(s):	Varsha Bhatt, Radhakrishnan Pillai, Arturo Angel
Assignee:	Bausch Health Ireland Ltd
Application Number:	US17/835,935
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,128,059
Patent Claim Types: see list of patent claims	Use; Formulation;

Scope & Claims Review and U.S. Patent Landscape for United States Drug Patent 12,128,059 (Clindamycin Phosphate + Benzoyl Peroxide + Adapalene Topical Gel)

Executive summary

• US 12,128,059 claims a specific triple-combination topical gel for inflammatory skin conditions (acutely tied to acne) combining clindamycin phosphate (1–1.5 wt%), benzoyl peroxide (2.5–3.5 wt%), and adapalene (~0.15–0.2 wt%), with a defined gel network (broad gelling-agent genus) plus polyhydric alcohol and water.
• The claim set is built to support (i) product infringement (gel composition), (ii) use infringement (method-of-treatment for acne with once-daily administration timing), and (iii) process infringement (premix-based manufacturing steps), and (iv) dispensing system infringement (pump-calibrated container).
• The strongest claim hooks are the numerical ranges, the gelling-agent selection, the microstructure controls (undissolved benzoyl peroxide particle size; optional adapalene undissolved fraction), and compatibility constraints (no oxidation reaction between adapalene and benzoyl peroxide).
• For competitive freedom-to-operate, the key risk is that design-arounds must avoid all of the following simultaneously: (a) the exact drug combination and wt% windows, (b) the defined gelling-agent “selected from” list, and (c) the formulation constraints (undissolved particle-size band, no oxidation, and gel/pH system).

---

What claims does US 12,128,059 cover for a clindamycin phosphate, benzoyl peroxide, adapalene topical gel?

Bottom line: Independent claim 1 is the central infringement anchor. Dependent claims narrow to specific wt% embodiments, specific gelling agents (carbomer Type C, crosslinked carboxylate polymers), and specific microstructure/compatibility features. Downstream method, container, and manufacturing claims create multiple infringement pathways.

Claim 1 (composition): what is required to infringe

A topical gel formulation comprising:

• Clindamycin phosphate: 1–1.5 wt%
• Benzoyl peroxide: 2.5–3.5 wt%
• Adapalene: ~0.15–0.2 wt%
• A gelling agent selected from a defined list
• A polyhydric alcohol
• Water

Gelling agent genus (selected from): hydroxypropylcellulose, hydroxyethylcellulose, carboxyvinyl polymers, crosslinked carboxyvinyl polymers with allyl ethers of polyalcohols, carboxyvinyl copolymers, polyacrylates, acrylate copolymers, acrylamide/sodium acryloyldimethyltaurate copolymers, polyvinyl alcohols, polyethylene oxides, propylene glycol alginates, methylcellulose, hydroxypropylmethylcellulose, xanthan gum, carrageenan gum, and combinations.

Infringement posture:

• If a competitor uses the same active combination and ranges but chooses a non-listed gelling agent, they likely avoid claim 1 (unless they still fall within another independent claim not provided here).
• If they use a listed gelling agent but their wt% values are outside the windows, they likely avoid claim 1.
• If all elements match, claim 1 is broad enough to capture multiple gel platforms, including polymeric cellulose systems, carbomer-like carboxyvinyl systems, acrylics, and natural gums.

Claim 2 and 3 (preferred numerical targets)

• Claim 2: “about 1.2 wt% clindamycin phosphate, about 3.1 wt% benzoyl peroxide, about 0.15 wt% adapalene.”
• Claim 3: explicit embodiment adding operational details:
  • propylene glycol ~5 wt%
  • carbomer homopolymer Type C ~1.75 wt%
  • KOH to set pH 5–6
  • water and the three actives at claim-2 levels

Practical meaning: These dependent claims pin down a lead formulation with a carbomer Type C gel matrix, an alkaline pH window, and propylene glycol as the polyhydric alcohol system.

Claims 4–7 (method of treating acne)

• Claim 4: treat inflammatory skin conditions via daily topical administration using the claimed gel.
• Claim 5: inflammatory skin condition is acne.
• Claim 6: “once daily” over at least 4 weeks.
• Claim 7: requires comparative efficacy: “more effective than” specified alternative formulations:
  1. clindamycin phosphate + benzoyl peroxide (no adapalene),
  2. benzoyl peroxide + adapalene (no clindamycin),
  3. clindamycin phosphate + adapalene (no benzoyl peroxide).

Evidentiary posture: Claim 7 sets up a litigation-friendly efficacy differentiation that can be attacked by designing clinical endpoints or by arguing the claim requires a specific comparative finding.

Claim 8 (drug container/pump dispensing)

• A drug container with a pump calibrated to release a specific amount each press, containing the claimed gel.

Risk implication: Even if composition is close, product packaging/labeling that enforces a fixed-dose pump could draw in additional defendants (manufacturer or packager) if the pump is integral to the “specific amount” calibration.

Claim 9 (making the gel: premix steps)

A multi-step method:

1. Provide premix A: dispersion of gelling agent in water
2. Premix B: dispersion of benzoyl peroxide in polyhydric alcohol and water
3. Premix C: clindamycin phosphate in aqueous solution
4. Premix D: micronized adapalene in polyhydric alcohol and water
5. Mix A and D
6. Admix B
7. Admix C
8. Adjust pH to 5–6 to form the gel

Infringement posture: Process claims are typically harder to prove without manufacturing records, but if a competitor uses the same premix logic (especially micronized adapalene dispersion in polyhydric alcohol and pH adjustment window), it can create discovery leverage.

---

Which formulation features inside US 12,128,059 narrow infringement risk (gelling agent, pH, polyhydric alcohol)?

Claim 10: carbomer homopolymer Type C

• Gelling agent comprises carbomer homopolymer Type C.

Design-around: switching to cellulose, natural gums, or non-carbomer acrylic systems avoids the specific dependent claim but may still infringe claim 1 if the new gelling agent remains in the claim-1 list.

Claim 11: crosslinked carboxy polymer + base

• Gelling agent is crosslinked carboxylate polymer; formulation includes base (KOH, NaOH, or both) sufficient to deprotonate carboxy moieties and thicken.

Design-around: using non-carboxylate thickening polymers or avoiding the base-thickening mechanism may reduce literal fit (for claim 11), though claim 1 can still capture if the gelling agent remains listed.

Claim 12: gelling agent amount 1.5–2 wt%

A quantity limiter that targets a typical gel viscosity platform.

Claims 16 and 18: polyhydric alcohol scope and amount

• Claim 16: polyhydric alcohol includes propylene glycol, ethoxydiglycol, polyethylene glycol, glycerol, or combinations.
• Claim 18: polyhydric alcohol 3–7 wt%.

Design-around: using a polyhydric alcohol outside the named list or outside the wt% band targets dependent claim avoidance. Claim 1 still requires “a polyhydric alcohol” but not the same narrowed list; however, claim construction and dependent claims can influence how the rest of the claim set is read in practice.

Claim 17: no additional organic solvents besides the polyhydric alcohol

If a competitor includes additional organic solvents, they may avoid claim 17 while still potentially falling within claim 1 if those solvents are “organic solvents other than polyhydric alcohol.”

Claim 19: free of ionic surfactants

This may matter for formulation stability and wetting. Avoiding ionic surfactants is a straightforward design-around for claim 19, but the broader claim 1 does not require surfactant absence.

---

How do the “undissolved particle size” and “no oxidation” limitations affect infringement and generic entry risk?

Claim 13: undissolved benzoyl peroxide with 1–50 micron mean particle size

• Requires benzoyl peroxide to have an undissolved fraction homogeneously dispersed.
• The mean particle size of the undissolved benzoyl peroxide: 1 to 50 microns.

Competitive impact:

• A formulator can avoid claim 13 by either fully dissolving/solubilizing benzoyl peroxide into the matrix (if feasible at these wt%) or by shifting the particle size outside 1–50 microns.
• If a product uses microcrystalline or colloidal benzoyl peroxide suspensions, particle characterization becomes a direct litigation fact.

Claim 14: optional undissolved adapalene fraction

• Requires undissolved adapalene similarly homogeneously dispersed.

Impact: This is likely a second microstructure hook that can be evaluated via microscopy/particle size distribution.

Claim 15: adapalene and benzoyl peroxide do not undergo oxidation reaction

This is an explicit compatibility/chemical stability constraint.

Risk: Competitors may reformulate but must demonstrate the “no oxidation” condition. In litigation, this becomes a test-question framed around analytical stability outcomes under relevant storage/usage conditions. If a competitor’s formulation shows measurable oxidation products, it may fail the dependent claim 15.

---

How strong is the patent estate for competitors: what are the main infringement theories built into US 12,128,059?

Structure of enforcement leverage in the provided claims:

1. Composition claim (Claim 1) enables broad product coverage.
2. Narrow embodiment claims (Claims 2–3, 10–12, 16, 18–19) create additional “fall-back” infringement points.
3. Method-of-use claims (Claims 4–7) extend protection to clinical practice and label-induced conduct if the prescribed regimen matches “once daily” for “at least 4 weeks” and efficacy superiority is shown.
4. Container claim (Claim 8) supports packaging/pump calibration theories.
5. Manufacturing process claim (Claim 9) supports process infringement and can be used strategically in discovery, even if literal infringement is contested.

Practical strength drivers:

• Numerical windows for actives reduce ambiguity and improve mapping of competitors’ INCI/label and testing data.
• Defined gel-maker list ties infringement to common polymer platforms but still provides a clear list that a defendant can try to avoid.
• Particle-size and chemical compatibility hooks raise the evidentiary bar for design-arounds.

---

What patents likely intersect with US 12,128,059’s scope (and where are the typical gaps)?

A complete U.S. landscape cannot be produced from the claim text alone because no bibliographic data (publication numbers, filing date, expiration, assignee, related continuations, citation set) is provided here. The following is limited to claim-logic intersections that commonly occur in the same therapeutic and formulation domain.

Potential intersection clusters implied by the claim set

• Triple-combination topical acne compositions using clindamycin + benzoyl peroxide + adapalene.
• Gel matrix thickener systems (cellulosics, carboxyvinyl polymers/carbomer, polyacrylates, polyvinyl alcohol, polyethylene oxides, alginates, natural gums).
• Particle engineering for dispersed oxidizers (benzoyl peroxide) and retinoids (adapalene).
• Stability/compatibility constraints to avoid oxidation between benzoyl peroxide and adapalene.

Where gaps usually appear

• Competitors often shift to different gelling-agent families or different particle size distributions, aiming to evade dependent claims like 13–15.
• If label-driven method-of-use claims exist, competitors may adjust dosing frequency or regimen duration; claim 6 requires “once daily” and “at least 4 weeks,” which is not always identical to generic label patterns.

---

What would a design-around have to change to avoid claim 1 and its core dependents?

To avoid claim 1 literal infringement, a competitor generally must change at least one of the major pillars:

1. Active wt% windows: move clindamycin, benzoyl peroxide, or adapalene outside the specified “about” ranges.
2. Gelling agent choice: select a thickener not listed in claim 1’s “selected from” list.
3. Remove the polyhydric alcohol or water gel architecture: use a different delivery format or remove gel requirements.

To avoid the strongest dependent claims without changing the core, a competitor may target:

• Particle size for undissolved benzoyl peroxide (claim 13)
• Presence of undissolved adapalene (claim 14)
• Demonstrated absence of oxidation reaction (claim 15)
• Carbomer Type C and pH 5–6 / KOH system (claims 3, 10, 11)

---

Key Takeaways

• US 12,128,059 is a triple-active topical acne gel patent with composition, method-of-use, manufacturing, and packaging claim coverage.
• The claim scope is driven by specific wt% ranges and a defined gelling-agent list, with additional narrowing through carbomer/pH/base, polyhydric alcohol identity and concentration, benzoyl peroxide particle-size control, and compatibility constraints.
• The most litigation-relevant technical questions are: gel thickener selection, whether benzoyl peroxide exists as an undissolved fraction with 1–50 micron mean particle size, whether adapalene oxidation products appear, and whether product instructions match once-daily dosing for at least 4 weeks.
• Design-around strategies that only adjust packaging or generic “inactive” choices are unlikely to suffice if the product remains within the core active and gel architecture.

---

FAQs

1. How can a competitor avoid US 12,128,059 if their benzoyl peroxide is fully dissolved?
   By eliminating an “undissolved fraction” and/or shifting benzoyl peroxide particle characterization outside the 1–50 micron mean size band, dependent claim coverage like claim 13 becomes difficult to maintain.

2. Does US 12,128,059 require a specific pH system for all infringing formulations?
   Not in claim 1 as written. The pH 5–6 requirement appears in dependent claim 3 and is part of the manufacturing method claim 9; it is not explicitly mandatory for claim 1.

3. What matters more for infringement: the gelling agent selection or the polyhydric alcohol identity?
   For claim 1, gelling agent selection is explicitly limited to the listed genus, while polyhydric alcohol is broadly required but then narrowed in dependent claims (e.g., claim 16 and 18).

4. Can a generic avoid method-of-use claims by changing dosing frequency?
   Claim 6 requires “once daily” over “at least 4 weeks.” A dosing regimen that materially departs from that labeled instruction can reduce method-of-use fit.

5. If a formulation matches the actives, can it still avoid dependent claim 15 by improving stability?
   Yes. Dependent claim 15 is framed as a “no oxidation reaction” limitation. Stability analytics showing oxidation does not occur under relevant conditions would be the compliance target.

---

References

1. United States Patent No. 12,128,059 (claims provided by user).

Drugs Protected by US Patent 12,128,059

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	CABTREO	adapalene; benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	216632-001	Oct 20, 2023		RX	Yes	Yes	12,128,059		Y			TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

International Family Members for US Patent 12,128,059

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020322173
Canada	3149296
China	114126582
China	119837892
Colombia	2022002253
European Patent Office	4007566